203 related articles for article (PubMed ID: 29102703)
1. On the role of salt formation and structural similarity of co-formers in co-amorphous drug delivery systems.
Wu W; Löbmann K; Rades T; Grohganz H
Int J Pharm; 2018 Jan; 535(1-2):86-94. PubMed ID: 29102703
[TBL] [Abstract][Full Text] [Related]
2. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
[TBL] [Abstract][Full Text] [Related]
3. Comparison of co-former performance in co-amorphous formulations: Single amino acids, amino acid physical mixtures, amino acid salts and dipeptides as co-formers.
Wu W; Grohganz H; Rades T; Löbmann K
Eur J Pharm Sci; 2021 Jan; 156():105582. PubMed ID: 33039568
[TBL] [Abstract][Full Text] [Related]
4. Nucleotides as new co-formers in co-amorphous systems: Enhanced dissolution rate, water solubility and physical stability.
Liu X; Shen L; Zhou L; Wu W; Liang G; Zhao Y; Wu W
Eur J Pharm Biopharm; 2024 Jul; 200():114333. PubMed ID: 38768766
[TBL] [Abstract][Full Text] [Related]
5. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
Jensen KT; Blaabjerg LI; Lenz E; Bohr A; Grohganz H; Kleinebudde P; Rades T; Löbmann K
J Pharm Pharmacol; 2016 May; 68(5):615-24. PubMed ID: 26245703
[TBL] [Abstract][Full Text] [Related]
6. Organic acids as co-formers for co-amorphous systems - Influence of variation in molar ratio on the physicochemical properties of the co-amorphous systems.
Wu W; Ueda H; Löbmann K; Rades T; Grohganz H
Eur J Pharm Biopharm; 2018 Oct; 131():25-32. PubMed ID: 30040997
[TBL] [Abstract][Full Text] [Related]
7. Poly (amino acid)s as new co-formers in amorphous solid dispersion.
Huang Q; Zou Z; Li X; Xiao Q; Liang G; Wu W
Int J Pharm; 2023 Mar; 634():122645. PubMed ID: 36706970
[TBL] [Abstract][Full Text] [Related]
8. Dipeptides as co-formers in co-amorphous systems.
Wu W; Löbmann K; Schnitzkewitz J; Knuhtsen A; Pedersen DS; Rades T; Grohganz H
Eur J Pharm Biopharm; 2019 Jan; 134():68-76. PubMed ID: 30468836
[TBL] [Abstract][Full Text] [Related]
9. Aspartame as a co-former in co-amorphous systems.
Wu W; Löbmann K; Schnitzkewitz J; Knuhtsen A; Pedersen DS; Grohganz H; Rades T
Int J Pharm; 2018 Oct; 549(1-2):380-387. PubMed ID: 30075253
[TBL] [Abstract][Full Text] [Related]
10. Application of a Salt Coformer in a Co-Amorphous Drug System Dramatically Enhances the Glass Transition Temperature: A Case Study of the Ternary System Carbamazepine, Citric Acid, and l-Arginine.
Ueda H; Wu W; Löbmann K; Grohganz H; Müllertz A; Rades T
Mol Pharm; 2018 May; 15(5):2036-2044. PubMed ID: 29630842
[TBL] [Abstract][Full Text] [Related]
11. Amorphous drug delivery systems: molecular aspects, design, and performance.
Kaushal AM; Gupta P; Bansal AK
Crit Rev Ther Drug Carrier Syst; 2004; 21(3):133-93. PubMed ID: 15248808
[TBL] [Abstract][Full Text] [Related]
12. Co-former selection for co-amorphous drug-amino acid formulations.
Kasten G; Löbmann K; Grohganz H; Rades T
Int J Pharm; 2019 Feb; 557():366-373. PubMed ID: 30578980
[TBL] [Abstract][Full Text] [Related]
13. Amino acids as co-amorphous stabilizers for poorly water-soluble drugs--Part 2: molecular interactions.
Löbmann K; Laitinen R; Strachan C; Rades T; Grohganz H
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):882-8. PubMed ID: 23567485
[TBL] [Abstract][Full Text] [Related]
14. Co-amorphous systems for the delivery of poorly water-soluble drugs: recent advances and an update.
Han J; Wei Y; Lu Y; Wang R; Zhang J; Gao Y; Qian S
Expert Opin Drug Deliv; 2020 Oct; 17(10):1411-1435. PubMed ID: 32683996
[TBL] [Abstract][Full Text] [Related]
15. Permeability of glibenclamide through a PAMPA membrane: The effect of co-amorphization.
Ruponen M; Visti M; Ojarinta R; Laitinen R
Eur J Pharm Biopharm; 2018 Aug; 129():247-256. PubMed ID: 29894814
[TBL] [Abstract][Full Text] [Related]
16. Solid-state properties and dissolution behaviour of tablets containing co-amorphous indomethacin-arginine.
Lenz E; Jensen KT; Blaabjerg LI; Knop K; Grohganz H; Löbmann K; Rades T; Kleinebudde P
Eur J Pharm Biopharm; 2015 Oct; 96():44-52. PubMed ID: 26197392
[TBL] [Abstract][Full Text] [Related]
17. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
[TBL] [Abstract][Full Text] [Related]
18. Spray drying of poorly soluble drugs from aqueous arginine solution.
Ojarinta R; Lerminiaux L; Laitinen R
Int J Pharm; 2017 Oct; 532(1):289-298. PubMed ID: 28890173
[TBL] [Abstract][Full Text] [Related]
19. Amorphization of Low Soluble Drug with Amino Acids to Improve Its Therapeutic Efficacy: a State-of-Art-Review.
Kapoor DU; Singh S; Sharma P; Prajapati BG
AAPS PharmSciTech; 2023 Dec; 24(8):253. PubMed ID: 38062314
[TBL] [Abstract][Full Text] [Related]
20. Amino acids as co-amorphous excipients for tackling the poor aqueous solubility of valsartan.
Huang Y; Zhang Q; Wang JR; Lin KL; Mei X
Pharm Dev Technol; 2017 Feb; 22(1):69-76. PubMed ID: 27050301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]